Skip to content

Ibogaine for addiction: all studies

Page 5 of 10: studies 41 to 50 of 93, newest first. Back to the ibogaine for addiction overview

Research

Novel treatment of opioid use disorder using ibogaine and iboga in two adults

Journal of Evolutionary Psychology March 30, 2020 Claire Wilson, Trevor Millar, Zak Matieschyn 11 citations

Abstract Ibogaine is a naturally occurring psychedelic medicine with anti-addictive properties. While research on ibogaine is limited, several observational studies have shown ibogaine can mitigate opioid withdrawal, as seen with reductions in clinical and subjective opioid withdrawal scores and reduced drug use severity (Noller, Frampton, & Yazar-Klosinski, 2018; Brown & Alper 2018)....

Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias.

The Journal of emergency medicine October 1, 2019 James Grogan, Roy R Gerona, Jerry W Snow et al. 16 citations

Ibogaine is a psychoactive indole alkaloid that has been investigated for use as a treatment for opioid addiction. While not commercially available in the United States, it is available via Internet suppliers. Ibogaine use has been associated with significant cardiac and neurologic effects, such as QT-segment prolongation, cardiac dysrhythmias, hallucinations, seizures, and central nervous...

Biosynthesis of an Anti-Addiction Agent from the Iboga Plant.

Journal of the American Chemical Society August 21, 2019 Scott C. Farrow, Mohamed O. Kamileen, Lorenzo Caputi et al. 69 citations

(-)-Ibogaine and (-)-voacangine are plant derived psychoactives that show promise as treatments for opioid addiction. However, these compounds are produced by hard to source plants, making these chemicals difficult for broad-scale use. Here we report the complete biosynthesis of (-)-voacangine, and de-esterified voacangine, which is converted to (-)-ibogaine by heating, enabling biocatalytic...

DOI: 10.1021/jacs.9b05999 (opens in new tab) Full text (opens in new tab) Substance abuse treatment Anti-addiction agents Opioid dependence solutions Biocatalysis: biocatalytic synthesis +10

On Addiction, Complexity, and Freedom: Toward a Liberation-Focused Addiction Treatment.

Journal of Psychoactive Drugs 2019 Scott Kellogg 4 citations

This article outlines a liberation-focused model of addiction treatment. Drawing on the Latin root word "addictus", addiction is seen as slavery and freedom, rather than the cessation of drug and alcohol use, is proposed as a viable, alternative treatment goal. Freedom is defined as: (1) the capacity to create a life of social and internal complexity and multiplicity; (2) the ability to make...

DOI: 10.1080/02791072.2018.1564157 (opens in new tab) Full text (opens in new tab) Ibogaine Addiction psychotherapy Addiction treatment Harm reduction +3

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.

Journal of Psychoactive Drugs 2019 Thomas K Brown, Geoff Noller, Julie O Denenberg 48 citations

This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire...

DOI: 10.1080/02791072.2019.1598603 (opens in new tab) Full text (opens in new tab) Hallucinogen Opioids Ibogaine therapy ibogaine Complete mystical experiences +1

Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.

Journal of Clinical Psychopharmacology December 1, 2018 Thomas Knuijver, Maarten Belgers, Wiebren Markus et al.

expressed in brain regions associated with emotional processing. Modulation of the hypothalamic-pituitary-adrenal axis by altering cortisol tone also seems to be involved in this effect. The ECS modulates stress and anxiety. Serum AEA and 2-AG levels are increased after stress, and AEA levels are negatively associated to baseline anxiety and are significantly reduced in womenwith major...

A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders

Journal of Psychedelic Studies June 1, 2018 Thaddeus James Camlin, Donald Eulert, A. Thomas Horvath et al. 21 citations

This study examined the lived experience of individuals who underwent ibogaine treatment for an opioid use disorder. Semi-structured interview questions probed for potential changes in predetermined categories derived from a literature review. Participants' experiences with ibogaine were analyzed for commonalities and emergent themes. Categories that emerged revealed themes about subjective...

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.

The American Journal of Drug and Alcohol Abuse 2018 Geoffrey E Noller, Chris M Frampton, Berra Yazar-Klosinski 150 citations

The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for opioid dependence. This...

DOI: 10.1080/00952990.2017.1310218 (opens in new tab) Full text (opens in new tab) Legal availability Opioid dependence Opioid detoxification Psychedelics +4

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.

The American Journal of Drug and Alcohol Abuse 2018 Thomas Kingsley Brown, Kenneth Alper 156 citations

Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. To study outcomes following opioid detoxification with ibogaine. In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5...